چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | مرضیه فتحی |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | مرکز تحقیقات ریز فناوری دارویی |
| کد مقاله | 78225 |
| عنوان فارسی مقاله | Recent advancement of nasal delivery for the treatment of Alzheimer's disease |
| عنوان لاتین مقاله | Recent advancement of nasal delivery for the treatment of Alzheimer's disease |
| نوع ارائه | سخنرانی |
| عنوان کنگره / همایش | چهارمین کنگره مجازی بین المللی التهاب سیستم عصبی |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | مشهد |
| سال انتشار/ ارائه شمسی | 1399 |
| سال انتشار/ارائه میلادی | 2021 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1399/12/14 الی 1399/12/15 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://cong-neuroinflammation.mums.ac.ir/files_site/files/r_21_210726043909.pdf |
| آدرس علمی (Affiliation) نویسنده متقاضی | Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences |
| نویسنده | نفر چندم مقاله |
|---|---|
| ملیکا لطفی | اول |
| مرضیه فتحی | دوم |
| خسرو ادیب کیا | سوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Alzheimer's disease (AD) is a progressive, chronic and irreversible neurodegenerative disease. This disease is caused by dysfunction of the central nervous system (CNS) and is associated with aging. AD, as the most common form of dementia, accounts for 70% of all dementia cases in the world. Many neurodegenerative diseases require the delivery of drugs to the brain. Considering the blood-brain barrier, drug delivery approaches for AD is limited. To conquer this problem, delivering the drug via nasal route seems to be appropriate as an alternative to systemic administration. Many drugs may be transported across the nasal membrane into the systemic circulation. After they are administered intranasally, these drugs cross the blood-brain barrier (BBB) to reach the brain and the cerebrospinal fluid (CSF). This pathway can be a potential option to improve the bioavailability of the drug considering hepatic/gastrointestinal first-pass effects. Additionally, to increase drug permeability across the olfactory epithelium, numerous drug delivery systems have been evaluated. The present review throws light on the latest discoveries of some of the crucial findings on intranasal drug delivery systems (DDSs) in AD, to understand the mechanism of transportation of DDSs from the nose to the CNS, along with stating clinical progress of DDSs. To this end, recent advances in AD nasal DDSs such as different types of hydrogels (hydrogels nanoparticles and nanocomposites, stimuli-responsive hydrogels, in-situ gelling hydrogels, biopolymer-based hydrogels), vesicular carriers (liposomes, niosomes), nanoparticles (micelles) and microparticles will be discussed and summarized. Furthermore, the clinical application of intranasal drug delivery to the brain for treating AD will need a long period time of research and clinical trials bring an optimistic aspect to the patients dealing with this type of dementia. |
| کلمات کلیدی | : Nasal drug delivery, Alzheimer's disease, Blood-brain barrier, Neurodegenerative diseases |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Lotfi et al.pdf | 1400/12/12 | 254330 | دانلود |
| Certificate.jpg | 1400/12/12 | 415544 | دانلود |
